CEO's On the Move

Medivir AB Appoints Christine Lind as CEO
04/28/2017
Medivir AB (publ) (MVIRB:SS:Stockholmsborsen - cash) Medivir AB announced that Christine Lind has been appointed as the new CEO of Medivir, effective as of 1 April 2017.

Upcoming Board Meetings

Luxottica Group S.p.A.
(LUX:IM:Milan Stock Exchange)
April 28, 2017
Luxottica Group SpA, Board Meeting, Apr 28, 2017. Agenda: To issue the consolidated net sales for the three-month period ended March 31, 2017.
Announced 12/15/16
Luxottica Group S.p.A. Key Board Members
Leonardo Del Vecchio
Founder, Executive Chairman, Chief Executive Officer and Executive President
Luigi Francavilla
Deputy Chairman, Chairman of Luxottica SRL and Managing Director of Luxottica SRL
Francesco Milleri
Deputy Chairman

Executive Changes

ERAMET Announces Executive Changes
04/28/17
ERAMET announced that on February 23, 2017, Mrs. Christel BORIES was appointed Deputy Chief Executive Officer by Mr. Patrick BUFFET, ERAMET Group Chairman & Chief Executive Officer.  Mrs. BORIES will be expected to succeed Mr. BUFFET at the conclusion of the General Meeting on May 23, 2017.
Zodiac Aerospace Appoints Yann Delabrière as Special Advisor to the Board; Provides Earnings Guidance for the Year 2017 and 2019
04/28/17
Board of Directors of Zodiac Aerospace has appointed Mr. Yann Delabrière, former Chairman and Chief Executive Officer of Faurecia, as Special Advisor to the Board to ensure close coordination between the Board of Directors and the operational teams to accelerate and deliver the industrial and operational recovery of the Group, which would facilitate a smooth integration of Zodiac Aerospace within the Safran Group should the ongoing discussions succeed In the event that negotiations with Safran do not result in an agreement, its mission will focus on the development of the Zodiac Group's standalone plan and any issues relevant to the implementation of the most effective operational governance for the future. Member of the Executive Committee, he will carry out his duties in coordination with the Executive Board and will report regularly to the Chairman of the Supervisory Board and to the Ad-hoc Committee set up within it to ensure follow-up. For the 2016/2017 fiscal year, the current operating income should be within a range of EUR 200 million to EUR 220 million. The Group maintains its target of a "mid-double digit" current operating margin by fiscal year 2018/2019.
Mast Therapeutics, Inc. Announces Management Changes
04/27/17
on April 27, 2017, Pursuant to the merger agreement with Savara Inc, Mast Therapeutics, Inc. announced that Howard C. Dittrich, Peter Greenleaf, and Brian M. Culley resigned from the Board and any respective committees of the Board on which they served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. Also, pursuant to the Merger Agreement, on April 27, 2017, effective as of the Effective Time, the company terminated the employment of Brian M. Culley, the Company’s Chief Executive Officer, Brandi L. Roberts, the Company’s Chief Financial Officer and Senior Vice President, Edwin Parsley, the Company’s Chief Medical Officer and Senior Vice President, and Shana Hood, the Company’s General Counsel, Vice President and Secretary. In connection with the termination of the employment, such officers resigned all of the positions they held with the company and its subsidiaries. Effective as of the effective time, the company’s board of directors appointed Robert Neville as the company’s Chairman and Chief Executive Officer, Taneli Jouhikainen as the company’s President and Chief Operating Officer, and David Lowrance as the company’s Chief Financial Officer. Each of the newly appointed executive officers of the company entered into the company’s standard form of indemnification agreement with the company on April 27, 2017. On April 27, 2017, Yuri Pikover and Richard Hawkins were appointed to the audit committee of the Board. David Ramsay will continue to serve as the chairman of the audit committee; Nevan Elam and Joseph McCracken were appointed to the compensation committee of the Board, and Nevan Elam was appointed as the chairman of the compensation committee. Matthew Pauls will continue to serve on the compensation committee; and Yuri Pikover, Nevan Elam and Joseph McCracken were appointed to the nominating and corporate governance committee of the Board, and Yuri Pikover was appointed as the chairman of the nominating and corporate governance committee.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Top Compensated Executives at MVIRB:SS

Name/TitleAnnual Compensation
There is no Top Compensated Executives data available.

Average Compensation in the Biotechnology Industry

Biotechnology
$473.3K
Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.